Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05568472 · ClinicalTrials.gov registry record · NA

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

A NA study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, sponsored by SWOG Cancer Research Network.

Active
Registry status
NA
Development phase
565
Enrollment target
20
Study locations

NCT05568472 is a NA study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8 that is active but no longer recruiting, run by SWOG Cancer Research Network. The registered enrollment target is 565 participants, above the 298-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (90% higher). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05568472, a NA study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, is active but no longer recruiting, sponsored by SWOG Cancer Research Network.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
565 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Questionnaire Administration
  • OTHER Best Practice
  • BEHAVIORAL Health Education
  • PROCEDURE Endocrine Drug Therapy

Study Locations (20)

California

  • Kaiser Permanente-Deer Valley Medical Center - Antioch
  • Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
  • PCR Oncology - Arroyo Grande
  • AIS Cancer Center at San Joaquin Community Hospital - Bakersfield
  • Marshall Cancer Center - Cameron Park
  • Mercy Cancer Center �� Carmichael - Carmichael
  • Mercy San Juan Medical Center - Carmichael
  • Epic Care-Dublin - Dublin
  • Kaiser Permanente Dublin - Dublin
  • Mercy Cancer Center - Elk Grove - Elk Grove
  • Bay Area Breast Surgeons Inc - Emeryville
  • Epic Care Partners in Cancer Care - Emeryville
  • Kaiser Permanente-Fremont - Fremont
  • Fresno Cancer Center - Fresno
  • Kaiser Permanente-Fresno - Fresno
  • Contra Costa Regional Medical Center - Martinez
  • Fremont - Rideout Cancer Center - Marysville
  • Kaiser Permanente-Modesto - Modesto

Arizona

  • Kingman Regional Medical Center - Kingman
  • Cancer Center at Saint Joseph's - Phoenix

Trial Details

FieldValue
Enrollment Target 565 participants
Start Date 2023-03-29
Est. Completion 2028-05-01
Phase NA

Sponsor

SWOG Cancer Research Network

270 total trials

What the Registry Record Tells You About NCT05568472

The ClinicalTrials.gov registry entry for NCT05568472 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 565 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 298-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (90% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Anatomic Stage III Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT05568472 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05568472 about?

NCT05568472 is a clinical study titled "Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study". This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with e...

What is the current status of trial NCT05568472?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 565 participants. The study started on 2023-03-29. Estimated completion is 2028-05-01.

What conditions does trial NCT05568472 study?

This clinical trial studies the following conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma.

What interventions are being tested in trial NCT05568472?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Best Practice (OTHER), Health Education (BEHAVIORAL), Endocrine Drug Therapy (PROCEDURE).

Who is sponsoring clinical trial NCT05568472?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05568472 being conducted?

This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anatomic Stage III Breast Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.